Publications by authors named "Markus Schaich"

Claim this Profile
R
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.
Stefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, Björn Steffen, Christoph Schliemann, Markus Schaich

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies.
Michael Sandherr, Jannik Stemler, Enrico Schalk, Tessa Hattenhauer, Marcus Hentrich, Markus Schaich

Lancet Reg Health Eur· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.
Leo Ruhnke, Marius Bill, Sven Zukunft, Jan-Niklas Eckardt, Silvia Schäfer, Markus Schaich

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
Christoph Röllig, Björn Steffen, Christoph Schliemann, Jan-Henrik Mikesch, Nael Alakel, Markus Schaich

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
David Baden, Sven Zukunft, Gema Hernandez, Nadine Wolgast, Sophie Steinhauser, Markus Schaich

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An aggressive mediastinal EBV-associated large B cell lymphoma.
Katrin S Kurz, Daniel Noerenberg, Markus Schaich, Wolfgang Bethge, Heike Horn

Histopathology· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Markus Schaich

Haematologica· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller, Markus Schaich

Lancet Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Jan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, Andreas Petzold, Tim Sauer, Markus Schaich

Leukemia· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience.
Julius C Enßle, Sebastian Wolf, Sebastian Scheich, Sarah Weber, Michael Kramer, Markus Schaich

Br J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.
Julia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, Sven Zukunft, Marita Hartwig, Markus Schaich

Blood Cancer J· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Florian H Heidel, Andreas Hochhaus, Markus Schaich

Ann Hematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, Friedrich Stölzel, Cristina Gil, Markus Schaich

Haematologica· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.
Jan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, Tim Sauer, Sebastian Scholl, Markus Schaich

Blood Cancer J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.
Jan-Niklas Eckardt, Friedrich Stölzel, Desiree Kunadt, Christoph Röllig, Sebastian Stasik, Markus Schaich

J Hematol Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
Jan M Middeke, Klaus H Metzeler, Christoph Röllig, Michael Krämer, Jan-Niklas Eckardt, Markus Schaich

Blood Adv· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Franziska Taube, Julia Annabell Georgi, Michael Kramer, Sebastian Stasik, Jan Moritz Middeke, Markus Schaich

Blood· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Christoph Röllig, Hubert Serve, Richard Noppeney, Maher Hanoun, Utz Krug, Markus Schaich

Leukemia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Sebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, Christoph Röllig, Alwin Krämer, Markus Schaich

Blood Adv· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preinfection laboratory parameters may predict COVID-19 severity in tumor patients.
Alexander Kiani, Romina Roesch, Clemens M Wendtner, Frank Kullmann, Thomas Kubin, Markus Schaich

Cancer Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of mutations - a registry based analysis.
Jan M Middeke, Raphael Teipel, Christoph Röllig, Sebastian Stasik, Armin Zebisch, Markus Schaich

Leuk Lymphoma· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss-of-Function Mutations of Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.
Jan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, Christoph Röllig, Alwin Krämer, Markus Schaich

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reevaluation of reference values for bone marrow differential counts in 236 healthy bone marrow donors.
Stefani Parmentier, Michael Kramer, Swetlana Weller, Ulrich Schuler, Rainer Ordemann, Markus Schaich

Ann Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia.
Desiree Kunadt, Christian Dransfeld, Claudia Dill, Maria Schmiedgen, Michael Kramer, Markus Schaich

Ann Hematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia.
Desiree Kunadt, Michael Kramer, Claudia Dill, Heidi Altmann, Lisa Wagenführ, Markus Schaich

Biomark Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis